A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Axitinib (Primary) ; Binimetinib (Primary) ; Encorafenib (Primary) ; Sasanlimab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Landscape 1011 Study
Sponsors Pfizer

17 Dec 2024 Status changed from active, no longer recruiting to discontinued.
10 Jul 2024 Planned End Date changed from 17 Jun 2024 to 31 Oct 2024.
09 Nov 2023 Planned End Date changed from 28 Jun 2024 to 17 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com